Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Akebia Therapeutics (AKBA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Akebia Therapeutics to Present at Upcoming February Investor Conferences

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 14.31 (+5.07%)
Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 14.31 (+5.07%)
Akebia Therapeutics Announces Positive Top-Line Results from Phase 2 Study of Vadadustat in Japanese Patients with Anemia Associated with Dialysis-Dependent Chronic Kidney Disease

-- Phase 3 Study of Non-Dialysis Patients in Japan Ongoing; Phase 3 Studies of Dialysis Patients to Begin in 2018 --

AKBA : 14.31 (+5.07%)
Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 14.31 (+5.07%)
Market Has Not Yet Noticed Potential in Akebia Therapeutics (AKBA); Have You?

Akebia Therapeutics (AKBA) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.

AKBA : 14.31 (+5.07%)
Falling Earnings Estimates Signal Weakness Ahead for Aerie Pharmaceuticals (AERI)

Aerie Pharmaceuticals (AERI) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

AERI : 52.50 (-3.14%)
AKBA : 14.31 (+5.07%)
The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics

The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics

SGMO : 22.20 (-0.22%)
SRPT : 63.22 (+0.56%)
AKBA : 14.31 (+5.07%)
CALA : 8.10 (+5.19%)
GLYC : 24.38 (+1.41%)
5 Top-Ranked Drug Stocks that are Broker Favorites

With the pharma and biotech sector bouncing back in 2017, here is a look at five drug stocks including Sarepta (SRPT) that are broker favorites.

SGMO : 22.20 (-0.22%)
SRPT : 63.22 (+0.56%)
AKBA : 14.31 (+5.07%)
INCY : 84.71 (-0.94%)
CALA : 8.10 (+5.19%)
PFE : 35.76 (-0.69%)
GLYC : 24.38 (+1.41%)
Concert Pharmaceuticals (CNCE) Soars: Stock Adds 5.7% in Session

Concert Pharmaceuticals (CNCE) saw its shares rise nearly 6% on the day.

CNCE : 21.41 (+1.37%)
AKBA : 14.31 (+5.07%)
Akebia Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 14.31 (+5.07%)
GlycoMimetics (GLYC) Jumps: Stock Rises 11.9%

GlycoMimetics (GLYC) was a big mover last session, as the company saw its shares nearly 10%on the day amid huge volumes.

AKBA : 14.31 (+5.07%)
GLYC : 24.38 (+1.41%)
Akebia Therapeutics to Participate in Upcoming Investor Conferences

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 14.31 (+5.07%)
Akebia Therapeutics Announces Third Quarter 2017 Financial Results

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 14.31 (+5.07%)
Invirsa Secures Seed Financing to Develop New Approach to Treating Common Infectious Diseases that Affect Millions Annually

Invirsa, an Ohio pharmaceutical company developing a new line of attack against common infectious diseases, has closed $520,000 in seed financing. The founding team is led by experienced...

AKBA : 14.31 (+5.07%)
ARPO : 4.7500 (+7.95%)
Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 14.31 (+5.07%)
Biotech Stock Performance Review -- Agenus, Akebia Therapeutics, Acorda Therapeutics, and Advaxis

If you want a Stock Review on AGEN, AKBA, ACOR, or ADXS then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. Today, DailyStockTracker.com features the Biotech...

ADXS : 2.51 (-3.09%)
AGEN : 4.80 (+2.13%)
AKBA : 14.31 (+5.07%)
ACOR : 26.10 (+3.16%)
Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 14.31 (+5.07%)
Akebia Announces Positive Top-Line Results from Phase 2 Study of Vadadustat in Japanese Patients with Non-Dialysis-Dependent Chronic Kidney Disease

--- Phase 3 Study in Japan Expected to Commence by Year-End 2017 -

AKBA : 14.31 (+5.07%)
BioMarin Says FDA Not Planning an AdCom for Pegvaliase BLA

The FDA currently shows no intent to hold an AdCom to discuss the BLA for BioMarin's (BMRN) pipeline candidate, pegvaliase.

AKBA : 14.31 (+5.07%)
BMRN : 84.21 (+0.43%)
ACAD : 30.43 (-2.00%)
ADRO : 6.10 (unch)
GTx's (GTXI) Enobosarm Positive in Phase II, Shares Down

GTx (GTXI) posts positive data from a phase II study of enobosarm for treating women with stress urinary incontinence. However, shares dip possibly with the release falling below market estimates.

AKBA : 14.31 (+5.07%)
ACAD : 30.43 (-2.00%)
ADRO : 6.10 (unch)
GTXI : 15.46 (-7.48%)

Van Meerten Stock Picks

Nvidia - My Favorite S\&P 500 Large Cap Stock
$NVDA Summary96% technical by signals.
NVDA -7.57
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Mar E-mini S&Ps ( ESH18 unch) this morning are down -0.05% and European stocks are down -0.57% after European manufacturing activity slowed more than expected this month. Losses were contained as the 10-year... Read More

Chart of the Day

Match Group Inc CS (MTCH)

Match Group (MTCH) is the Barchart Chart of the Day.  The popular on-line dating company has a Trend Spotter buy signal, a Weighted Alpha of 190.79+ and gained 152.84% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures showed fractional gains on Wednesday. The weekly EIA report will be delayed until Thursday morning, as ethanol production fell to 1.016 million bpd in last week’s report. Ahead of the USDA Ag Outlook Forum, a Reuters survey of anal...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.